Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

Join me as I recount my journey to Osama bin Laden’s compound in Pakistan. This video covers the unique route I took, the ...

Soft copper wire : 20 gauge (wire diameter 0.8mm): 40cm (16 inch) about 5cm for each detail 4 cm (about 1.5 inch) for each ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

Advanced Micro Devices ( AMD -1.39%) upped its Q3 revenue guidance to $8.4 billion to $9 billion, and Q2's $7.7 billion ...

The popularity of Novo Nordisk's anti-diabetes and weight-loss treatments Ozempic and Wegovy had once made it a darling of ...

Danish pharma giant Novo Nordisk reports 32% rise in Q2 net profit to $4.1B, driven by strong sales of Ozempic and Wegovy ...

Novo Nordisk (NVO) stock was down pre-market after the company missed on top and bottom lines of second quarter earnings ...

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

OpenAI-backed start-up Chai Discovery has raised $70mn, valuing the group at about $550mn, as investors bet on the potential for artificial intelligence to speed up drug discovery and tackle disease.